Lucid Group Communications is a specialist provider of strategic medical communications services to global pharmaceutical companies.

Lucid Group provides medical education, medical communication, strategic consultancy and digital services to clients to drive better disease and patient management. 

Over the last twelve years, Lucid Group has become well known and admired as an industry leader in providing medical communication that transforms patients’ lives.  Currently it has five family members within its Group; Bluedog, Leading Edge, Lighthouse, Lucid Partners and ViVid, all of which comprise uniquely talented individuals with a vision to deliver life changing value for clients and patients.

In June 2017 LDC completed an £11million minority investment in Lucid Group Communications.

Founded in 2007 by Jan Steele and Dennis O’Brien, who will both continue to lead the business, the investment is enabling Lucid to continue to build infrastructure to support its rapid growth, ensuring that its services and offerings remain of the highest quality. It also enables Lucid to build a stronger market presence in the US, where the business launched in 2016. 

In addition, the investment is supporting Lucid to build its digital and creative capability, to broaden support for clients. 

In 2018 Lucid Group were named Communications Consultancy of the year and Medical Educations Consultancy of the Year at the Communiqué Awards - which celebrates exceptional healthcare communications work. The award’s judging panel was “spellbound” by the group’s performance this year stating “Lucid showed a sustained growth of 30% in a year that also saw a 46% surge in headcount and introduced flexible working.” They also said the group “demonstrated the authenticity of their patient centric approach showing a true focus on patient outcomes” and were impressed with Lucid’s investment in their team.

The Communiqué Awards also saw Lucid work its magic in two other categories, one of which was The Porterhouse Medical Group Award for Excellence in Professional Education Programmes for its two-year hidradenitis suppurativa campaign for AbbVie and Lucid’s work in multiple sclerosis for Sanofi Genzyme  in the Excellence in Communications via Meetings category.

In February 2019 Lucid Group completed its first acquisition, welcoming colleagues from creative and digital consultancy Bluedog into the Group. Lucid Group clients will experience significant benefits from this new relationship with direct access to cutting-edge digital expertise that will help engage today’s stakeholders and change behaviour more effectively to improve patient outcomes.

Just six months later in September, Lucid Group announced its latest acquisition, welcoming colleagues from Healthcare consultancy HEALTHCARE 21.

Both Lucid Group and HealthCare21 clients will experience significant benefits from this new relationship with direct access to diverse, larger teams, cutting-edge editorial expertise, an immediate larger footprint in the North West of the UK, with an ambition to build rapidly, taking advantage of the wealth of Healthcare communications talent based in this location. The presence of offices in Singapore and Dubai will also allow expansion into these geographies; which will benefit our global clients.

We felt the time was right to bring on board a strategic partner, and in LDC we have an experienced investor with a strong track record in the healthcare sector. From the outset, they have had a flexible approach to the investment, structuring the deal on terms that worked for us.
Dennis O'Brien, CEO, Lucid